ArticleJournal of cellular and molecular medicine2026
Yougui Pills Alleviate Osteoporosis by Inhibiting Mesenchymal Stem Cell ROS Accumulation via the Nrf2/HO-1 Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Osteoporosis (OP) is a prevalent skeletal disorder characterized by progressive bone mass loss and deteriorated microarchitecture, in which oxidative stress-induced mesenchymal stem cell (MSC) dysfunction serves as a core pathogenic mechanism. Yougui Pills (YGPs), a classical traditional Chinese medicine formula, are widely applied in clinical OP management, yet the cellular and molecular mechanisms underlying their anti-osteoporotic effects remain incompletely defined. This study aimed to elucidate the bone-protective role of YGPs in OP and explore the underlying mechanism, focusing on oxidative stress modulation in MSCs and the Nrf2/HO-1 signalling pathway. The bioactive components of YGPs and YGP-containing serum were characterized via UPLC. In vivo, an ovariectomy (OVX) mouse model was established to evaluate YGPs' effects on bone mass, trabecular microstructure and osteogenesis using micro-CT, histological and immunohistochemical assays; public GEO datasets were re-analysed to profile transcriptomic alterations and oxidative stress signatures in OP-derived MSCs. In vitro, H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.